Quick-Med Technologies Inc (QMDT)

[Penny Stocks 2.0]

PHASE 2 Quick-Med Technologies, Inc. (OTCBB: QMDT) (the "Company") today confirmed receipt of a Phase II Small Business Innovative Research ("SBIR") grant of $770,000 from the U.S. Army. The contract continues the Company's innovative research intended to develop a prototype wound dressing to speed healing of wounds from chemical blistering agents. The wound dressing being developed is based on advancements in the Company's NIMBUS(TM) technology. On July 26, 2006 the Company announced that it had been competitively selected for this grant, subject to availability of Federal funds and successful contract negotiations. Today's announcement confirms amounts and completion of the contract.

The NIMBUS technology process permanently binds polymeric antimicrobial onto surfaces that include cellulosics such as cotton and rayon, as well as various synthetics. This process enables the economical preparation of high performance wound dressings, fabrics and other medical and consumer products.

"We are very pleased with this Phase II grant from the U.S. Army," commented David S. Lerner, president of Quick-Med Technologies. "This grant will accelerate our development of advanced wound care products."

During Phase I of the grant, Quick-Med Technologies completed feasibility studies and proof of concept. The Phase II SBIR grant is worth $770,000, including $40,000 of additional funding under a Phase I (option) invoked by the U.S. Army. The total value of this contract for Phase I, Phase I (option), and Phase II is $840,000. Work under this contract is expected to be completed by 2009.

This work is supported by the U.S. Army Medical Research and Material Command under Contract No. W81XWH-06-C-0024. The Department of Defense's SBIR program was developed to stimulate technological innovation to meet military as well as commercial needs.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Quick-Med Technologies, Inc. is a life sciences company focused on developing broad-based technologies within the healthcare and consumer markets. The Company's two core products under development are the (1) NIMBUS(TM), a technology employing advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer products; and (2) MultiStat(TM) family of advanced patented methods and compounds, shown to be effective in key skin care therapy applications for cosmetic, military, and medical markets. Quick-Med Technologies, Inc. is listed under the symbol "QMDT" on the OTC Bulletin Board.

For additional information, visit Quick-Med Technologies' website: http://www.quickmedtech.com or email at [e-mail]. For Details, Contact: Natasha A. Sorobey at [phone]

(C) 2006 Quick-Med Technologies, Inc. All rights reserved. NIMBUS (TM) and MultiStat (TM) are trademarks of Quick-Med Technologies, Inc. All other trademarks are the property of their respective owners.